Drugs / GUB-UCN2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07702890 | Jul 2026 → Dec 2028 expected | obesity disorder, type 2 diabetes mellitus | Gubra A/S | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Gubra A/S | Regulatory Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 gubra.dk ↗
Gubra today announces that a clinical trial application (CTA) for the first-in-human study of GUB-UCN2, the company’s lead asset for high quality weight loss, has been submitted to the Competent Authority and associated Ethics Committee in Germany. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Gubra A/S | Gubra announces initiation of ambitious Phase 1/2a clinical trial of lead asset GUB-UCN2 in obesity gubra.dk ↗ |
| 2026-02-26 | Gubra A/S | Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 gubra.dk ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GUB-UCN2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07702890 ↗ |
| Route | Subcutaneous | “GUB-UCN2 will be administered subcutaneously” NCT07702890 ↗ |